Published in Dtsch Arztebl Int on May 11, 2012
De novo acute heart failure and acutely decompensated chronic heart failure. Dtsch Arztebl Int (2015) 1.93
Ventricular Assist Device in Acute Myocardial Infarction. J Am Coll Cardiol (2016) 1.46
Practice of hemodynamic monitoring and management in German, Austrian, and Swiss intensive care units: the multicenter cross-sectional ICU-CardioMan Study. Ann Intensive Care (2016) 1.40
An insight into short- and long-term mechanical circulatory support systems. Clin Res Cardiol (2014) 1.07
Angiopoietin-2 and outcome in patients with acute decompensated heart failure. Clin Res Cardiol (2014) 0.85
FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock. Eur Heart J Acute Cardiovasc Care (2013) 0.83
Efficacy and limitations of a STEMI network: 3 years of experience within the myocardial infarction network of the region of Augsburg - HERA. Clin Res Cardiol (2013) 0.81
The Th17/Treg imbalance in patients with cardiogenic shock. Clin Res Cardiol (2013) 0.78
Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit. Ann Intensive Care (2016) 0.77
Prognostic impact of ICG-PDR in patients with hypoxic hepatitis. Ann Intensive Care (2015) 0.76
Extensive variability in vasoactive agent therapy: a nationwide survey in Chinese intensive care units. Chin Med J (Engl) (2015) 0.76
Circulating bile acids predict outcome in critically ill patients. Ann Intensive Care (2017) 0.75
The impact of mild induced hypothermia on the rate of transfusion and the mortality in severely injured patients: a retrospective multi-centre study. Eur J Med Res (2016) 0.75
Insular infarct size but not levosimendan influenced myocardial injury triggered by cerebral ischemia in rats. Exp Brain Res (2014) 0.75
[Use of ECMO in adult patients with cardiogenic shock: a position paper of the Austrian Society of Cardiology]. Wien Klin Wochenschr (2015) 0.75
Outcome of elderly undergoing extracorporeal life support in refractory cardiogenic shock. Clin Res Cardiol (2017) 0.75
Intensive versus conventional glucose control in critically ill patients. N Engl J Med (2009) 26.30
Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med (2010) 8.58
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med (1999) 6.93
A tale of coronary artery disease and myocardial infarction. N Engl J Med (2012) 4.53
Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med (2008) 3.50
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA (2007) 3.48
A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J (2009) 3.06
Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med (2006) 2.47
Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA (2006) 2.35
Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med (2009) 2.16
One-year survival following early revascularization for cardiogenic shock. JAMA (2001) 2.10
Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med (2010) 1.84
The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail (2003) 1.82
Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol (2004) 1.77
Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J (2012) 1.65
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol (2002) 1.49
Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med (2005) 1.12
European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. Resuscitation (2010) 0.95
Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac disease. Am Heart J (2007) 0.95
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev (2011) 0.94
Characteristics and clinical outcome of 458 patients with acute myocardial infarction requiring mechanical ventilation. Results of the BEAT registry of the ALKK-study group. Clin Res Cardiol (2010) 0.93
Postresuscitation care: entering a new era. Curr Opin Crit Care (2010) 0.89
Glucose-insulin-potassium infusion and mortality in the CREATE-ECLA trial. JAMA (2005) 0.87
Use of mechanical assist during high-risk PCI and STEMI with cardiogenic shock. Catheter Cardiovasc Interv (2010) 0.78
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol (2008) 2.49
Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med (2006) 2.39
Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation (2002) 2.20
Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med (2009) 2.16
Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol (2010) 2.04
CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res (2010) 2.02
Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med (2005) 1.99
Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med (2002) 1.96
Intravascular embolization of venous catheter--causes, clinical signs, and management: a systematic review. JPEN J Parenter Enteral Nutr (2009) 1.94
Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med (2010) 1.84
Intravenous port catheter embolization: mechanisms, clinical features, and management. Angiology (2008) 1.78
Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation (2009) 1.76
Ca2+/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca2+ leak in human cardiac pathology. Circulation (2013) 1.67
Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome. Crit Care Med (2008) 1.66
Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med (2006) 1.58
Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. Crit Care Med (2009) 1.48
Limitations of FKBP12.6-directed treatment strategies for maladaptive cardiac remodeling and heart failure. J Mol Cell Cardiol (2010) 1.46
Levosimendan in cardiogenic shock: the magic drug for every patient? Crit Care Med (2007) 1.46
Transcoronary pacing in a porcine model--impact of guidewire insulation. J Invasive Cardiol (2011) 1.42
Leukotriene-mediated coronary vasoconstriction and loss of myocardial contractility evoked by low doses of Escherichia coli hemolysin in perfused rat hearts. Crit Care Med (2003) 1.41
Thrombolytic therapy in pregnancy. J Thromb Thrombolysis (2006) 1.36
Septic cardiomyopathy - A not yet discovered cardiomyopathy? Exp Clin Cardiol (2006) 1.36
Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J (2005) 1.31
Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol (2010) 1.27
Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab (Lond) (2006) 1.20
Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med (2006) 1.15
Activated polymorphonuclear leukocytes rapidly synthesize retinoic acid receptor-alpha: a mechanism for translational control of transcriptional events. J Exp Med (2004) 1.13
Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms. Innate Immun (2008) 1.13
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv (2012) 1.11
Port catheter insufficiency: incidence and clinical-radiological correlations. Onkologie (2008) 1.11
Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med (2002) 1.09
Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation (2007) 1.06
Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res (2010) 1.05
Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med (2008) 1.03
Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy. Shock (2008) 1.03
Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med (2002) 1.02
The role of ST-segment elevation in lead aVR in the risk assessment of patients with acute pulmonary embolism. Clin Res Cardiol (2011) 1.01
Myocardial ischemia/reperfusion causes VDAC phosphorylation which is reduced by cardioprotection with a p38 MAP kinase inhibitor. Proteomics (2007) 1.01
Prognosis of patients who develop acute renal failure during the first 24 hours of cardiogenic shock after myocardial infarction. Am J Med (2002) 0.99
Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother (2003) 0.95
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev (2015) 0.95
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev (2011) 0.94
Impedance cardiography: a useful and reliable tool in optimization of cardiac resynchronization devices. Europace (2007) 0.93
Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol (2012) 0.92
Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother (2005) 0.91
Cardiac surgery in Germany during 2007: a report on behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg (2008) 0.90
Inhibition of p53 after acute myocardial infarction: reduction of apoptosis is counteracted by disturbed scar formation and cardiac rupture. J Mol Cell Cardiol (2010) 0.90
Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone treatment. Eur J Heart Fail (2006) 0.89
Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. Am Heart J (2009) 0.89
Staphylococcus aureus alpha-toxin and Escherichia coli hemolysin impair cardiac regional perfusion and contractile function by activating myocardial eicosanoid metabolism in isolated rat hearts. Crit Care Med (2009) 0.89
Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol (2012) 0.88
Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances IL-6 and MCP-1 production. Am J Physiol Heart Circ Physiol (2009) 0.88
Atypical pulmonary embolism of port catheter fragments in oncology patients. Support Care Cancer (2006) 0.88
E2F2 expression induces proliferation of terminally differentiated cardiomyocytes in vivo. Cardiovasc Res (2008) 0.88
Regression of left ventricular mass one year after aortic valve replacement for pure severe aortic stenosis. Am J Cardiol (2002) 0.87
PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J Lipid Res (2008) 0.87
Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits. Proteomics (2002) 0.87
[Guidelines for intensive care in cardiac surgery patients: haemodynamic monitoring and cardio-circulatory treatment guidelines of the German Society for Thoracic and Cardiovascular Surgery and the German Society of Anaesthesiology and Intensive Care Medicine]. Thorac Cardiovasc Surg (2007) 0.87
K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum. Basic Res Cardiol (2009) 0.87
Comparison of chromosomal aberrations in primary colorectal carcinomas to their pulmonary metastases. Cancer Genet (2011) 0.87
Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg (2003) 0.86
Angiotensin II and myosin light-chain phosphorylation contribute to the stretch-induced slow force response in human atrial myocardium. Cardiovasc Res (2008) 0.86
Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J Cell Mol Med (2011) 0.86
Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive Care Med (2003) 0.86
Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol (2012) 0.85
Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med (2011) 0.85
Surgical treatment of pulmonary aspergillosis/mycosis in immunocompromised patients. Interact Cardiovasc Thorac Surg (2008) 0.85
In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res (2010) 0.85
Patients with insulin-dependent diabetes or coronary heart disease following rehabilitation express serum fractalkine levels similar to those in healthy control subjects. Vasc Health Risk Manag (2009) 0.84
Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev (2014) 0.84
Mechanisms of cardiac depression caused by lipoteichoic acids from Staphylococcus aureus in isolated rat hearts. Circulation (2005) 0.84
The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study. Catheter Cardiovasc Interv (2013) 0.84
Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition. J Cardiovasc Pharmacol (2008) 0.84
Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months? EuroIntervention (2013) 0.83
[Percutaneous renal denervation in patients with resistant hypertension--first experiences in Austria]. Wien Klin Wochenschr (2010) 0.83
Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium. Eur J Heart Fail (2008) 0.83
Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.83
Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience. Med Klin (Munich) (2008) 0.83
Gene expression profiling of human stenotic aorto-coronary bypass grafts by cDNA array analysis. Eur J Cardiothorac Surg (2003) 0.83
Expression of the leptin receptor in different types of vascular lesions. Histochem Cell Biol (2007) 0.83
Relation between renal dysfunction requiring renal replacement therapy and promoter polymorphism of the erythropoietin gene in cardiac surgery. Artif Organs (2010) 0.83
Phospholipid transfer protein in hemodialysis patients. Am J Nephrol (2007) 0.82
Strategic target temperature management in myocardial infarction--a feasibility trial. Heart (2013) 0.82
Cardioprotective effects of the serine protease inhibitor aprotinin after regional ischemia and reperfusion on the beating heart. J Thorac Cardiovasc Surg (2002) 0.82
An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J Am Coll Cardiol (2005) 0.81
Prognostic value of chromosomal imbalances in squamous cell carcinoma and adenocarcinoma of the lung. Ann Thorac Surg (2011) 0.81
Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting. Vasc Health Risk Manag (2011) 0.80
Plasma concentrations of von Willebrand factor and intracellular adhesion molecule-1 for prediction of outcome after successful cardiopulmonary resuscitation. Crit Care Med (2003) 0.80
Impact of the learning curve on outcomes after percutaneous mitral valve repair with MitraClip and lessons learned after the first 75 consecutive patients. Eur J Heart Fail (2011) 0.80
Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis (2011) 0.80
Hypothermic renal protection using cold histidine-tryptophan-ketoglutarate solution perfusion in suprarenal aortic surgery. Ann Vasc Surg (2008) 0.80
Miniaturized HIA microdiagonal pump as left ventricular assist device in a sheep model. ASAIO J (2008) 0.80
Methylprednisolone fails to preserve pulmonary surfactant and blood-air barrier integrity in a porcine cardiopulmonary bypass model. J Surg Res (2007) 0.80
The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro. Thromb Haemost (2010) 0.80
Nerve localization for peripheral regional anesthesia. Recommendations of the German Society of Anaesthesiology and Intensive Care Medicine. Anaesthesist (2014) 0.80